Proactiveinvestors Australia - Pharmaceuticals RSS feed Proactiveinvestors Australia - Pharmaceuticals feed en Sun, 21 Jan 2018 17:09:15 +1100 Genera CMS AusCann Group to collaborate in enhancing medicinal cannabis production Wed, 17 Jan 2018 14:47:00 +1100 Auscann Group’s shares surge following green light for medicinal cannabis export Thu, 04 Jan 2018 14:35:00 +1100 AusCann Group Holdings advances medical cannabis supply chain strategy Mon, 18 Dec 2017 14:51:00 +1100 AusCann Group Holdings shares pop on grant of new medical cannabis licence Thu, 07 Dec 2017 10:59:00 +1100 AusCann Group Holdings to reveal next medical cannabis steps in Australia Wed, 06 Dec 2017 10:04:00 +1100 AusCann Group Holdings secures medical cannabis cultivation licence Wed, 22 Nov 2017 10:44:00 +1100 AusCann Group Holdings to reveal medical cannabis joint venture update Tue, 21 Nov 2017 10:00:00 +1100 AusCann Group Holdings welcomes medical cannabis legislation Fri, 20 Oct 2017 16:27:00 +1100 Botanix Pharmaceuticals to commence acne treatment patient study Tue, 22 Aug 2017 08:50:00 +1000 Botanix Pharmaceuticals' shares halted pending ethics approval update Thu, 17 Aug 2017 10:34:00 +1000 AusCann Group Holdings Ltd granted Australian medicinal cannabis manufacturing licence Wed, 09 Aug 2017 13:22:00 +1000 ImpediMed enrols first patient in chronic heart failure trial Tue, 08 Aug 2017 15:44:00 +1000 AusCann Group to outline next medicinal cannabis steps in Australia Tue, 08 Aug 2017 13:02:00 +1000 Cogstate Ltd to update on submission to U.S. FDA Wed, 26 Jul 2017 09:41:00 +1000 AusCann Group Holdings Ltd secures two licences Tue, 11 Jul 2017 10:00:00 +1000 Botanix Pharmaceuticals Ltd crosses a milestone in product development Mon, 03 Jul 2017 12:00:00 +1000 Botanix Pharmaceuticals to reveal clinical results Fri, 30 Jun 2017 12:00:00 +1000 AusCann Group Holdings makes new appointments Thu, 15 Jun 2017 15:00:00 +1000 ImpediMed begins lymphoedema study using its health device Thu, 15 Jun 2017 09:00:00 +1000 AusCann Group Holdings welcomes regulatory change Wed, 14 Jun 2017 10:00:00 +1000 Botanix Pharmaceuticals raises $7.4M to advance product development Mon, 22 May 2017 11:00:00 +1000 AusCann Group Holdings secures medical cannabis funding Fri, 19 May 2017 13:00:00 +1000 AusCann Group Holdings in halt ahead of capital raising Wed, 17 May 2017 11:00:00 +1000 AusCann Group Holdings partners with Tasmanian Alkaloids Wed, 17 May 2017 09:00:00 +1000 Botanix Pharmaceuticals begins first clinical study of acne product Mon, 08 May 2017 10:30:00 +1000 AusCann Group Holdings wins medical cannabis licence Fri, 05 May 2017 12:00:00 +1000 AusCann Group Holdings in an ASX trading halt pending update Thu, 04 May 2017 10:30:00 +1000 AusCann Group Holdings harvesting first crop in Chile Mon, 10 Apr 2017 12:00:00 +1000 Botanix Pharmaceuticals raising $7.4M for synthetic cannabidiol products Wed, 05 Apr 2017 11:00:00 +1000 AusCann Group Holdings to benefit from federal government changes Thu, 23 Feb 2017 11:30:00 +1100 Auscann Group Holdings positioned to be a leading supplier of Australian cannabinoid Elaine Darby, managing director for AusCann Group Holdings, speaks with Proactive Investors.

Thu, 17 Aug 2017 08:30:00 +1000
Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the orphan drug space ... acromegaly is exactly that, it is classified as an orphan condition with an estimated prevalence of 60 patients per million of population''.
''Orphan status is the same in Europe and the USA - it's designed to encourage companies like ourselves to develop treatments for rare conditions. We get marketing exclusivity and also don't require the same number of patients for clinical trials'', Nealon added. Amryt has already been awarded orphan drug status for its lead drug EpiSalven, to treat the skin disorder Epidermolysis Bullosa, which is being prepared for a phase III trial early next year.

Tue, 08 Nov 2016 01:10:00 +1100
Faron Pharmaceuticals Oy boss pleased with healthier than expected cash balance Faron Pharmaceuticals Oy (LON:FARN) ended the first half of 2016 with more cash than it had anticipated.

Research & development (R&D) expenses more than doubled, but the combination of higher than anticipated income, in the form of both revenue and grant income, and lower operating costs meant the company experienced only a modest cash outflow over the reporting period.

Chief executive Dr Markku Jalkanen told Proactive revenue comprised mostly of a €750,000 signing fee from Pharmbio and a €356,500 pre-payment relating to IFB-beta production.

The group also received €968,000 from the European Union from its FP7 Traumakine grant.

The company had a cash balance of €8.9mln at the end of June, it revealed in its results for the first half of the year.

Wed, 07 Sep 2016 00:25:00 +1000